ABSTRACT

**Background:** Somatic symptom disorders are common, disabling, and costly. Individually provided short-term psychodynamic psychotherapies (STPP) have shown promising results. However, the effectiveness of STPP for somatic symptom disorders has not been reviewed.

**Methods:** We undertook a systematic review of randomized controlled trials (RCTs) and controlled before and after studies. Outcomes included psychological symptoms, physical symptoms, social-occupational function, healthcare utilization and treatment continuation.

**Results:** A total of 23 studies met inclusion criteria and cover a broad range of somatic disorders. Thirteen were RCTs and 10 were case series with pre-post outcome assessment. Of included studies, 21/23 (91.3%), 11/12 (91.6%), 16/19 (76.2%) and 7/9 (77.8%) reported significant or possible effects on physical symptoms, psychological symptoms, social-occupational function and healthcare utilization respectively. Meta-analysis was possible for 14 studies and revealed significant effects on physical symptoms, psychiatric symptoms and social adjustment which were maintained in long term follow-up. Random effects modeling attenuated some of these relationships. There was 54% greater treatment retention in the STPP group versus controls.

**Conclusion:** STPP may be effective for a range of medical and physical conditions underscoring the role of patient’s emotional adjustment in overall health. Future research should include high quality randomized and clinical effectiveness studies with attention to healthcare use and costs.

Half of all outpatient medical visits are related to somatic complaints, of which at least one-third to one-half are medically unexplained. [1] Many are individual physical symptoms, such as pain (e.g., low back, joint, chest, abdominal, headache) and nonpain (e.g., fatigue, dizziness, palpitations) complaints. Others consist of a cluster of somatic symptoms for which the etiology is poorly understood such as irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, temporomandibular disorder and interstitial cystitis. These functional somatic syndromes often overlap and are similar in terms of psychiatric comorbidity, functional impairment, and family history. [2,3,4]

Distressing somatic symptoms are also increased two- to three-fold in patients with depressive and anxiety disorders. [5,6] More recently, it has also been shown that disease-specific somatic symptoms in patients with a variety of medical disorders are influenced as much by psychological factors as by the severity of the underlying medical disorder. [7,8] While some patients with medically unexplained symptoms meet criteria for somatoform disorders, the boundaries are not always clearcut between somatoform symptoms and the distressing and persistent somatic symptoms experienced by patients with functional somatic disorders, depression, anxiety, and even some medical conditions. [8]

Treatment of somatoform disorders and related conditions manifested by poorly explained somatic symptoms has been covered in several recent comprehensive reviews. [9, 10, 11, 12, 13, 14, 15] Cumulatively, these reviews confirm that two of the most evidence-based treatments are cognitive-behavioral therapy (CBT) and antidepressants. Too few studies of other treatments were then found to lend themselves to a meta-analysis.
Unresolved unconscious emotional issues have long been considered an important causal factor in a range of physical illnesses and somatic symptom disorders. [16] In clinical practice, psychodynamic psychotherapies focus on this unconscious process by which emotions translate into somatic symptoms, somatic focus, and, indeed, objectively measurable physical sequelae.

Short-term Psychodynamic Psychotherapies (STPP) are a group of brief therapy methods developed over the past 50 years by proponents including Mann, Sifneos, Malan and Davanloo. [17] Some STPP methods aim for insight into various unconscious phenomena while others seek to address alexithymia, or difficulty identifying and experiencing emotions. With these different goals, technical differences have developed over time with some methods being more versus less focused on emotional experiencing. They share the common goals of making unconscious phenomena conscious and working through underlying conflicts.

The efficacy of STPP across a range of common mental disorders was reviewed in two recent meta-analyses. [18,19] There are limitations to the generalisability of these findings to the treatment of somatic disorders. One review only included a single study with somatoform disorders [18], and the other excluded studies with formal psychotherapy treatment controls. Both reviews were restricted to RCTs of individual STPP methods. Thus, the great majority of all STPP studies for somatic symptom disorders have never been reviewed. The purpose of this paper is to critically review and meta-analyze where appropriate, data from studies using both RCT and non-RCT designs in order to examine the effectiveness of STPP in patients with somatic symptom disorders.

METHODS

Selection of studies

We included studies of STPP therapies in somatic symptom disorders covering both medically explained and unexplained symptoms without regard to the presence of a formal psychiatric disorder to better reflect the case mix seen in general medical settings. We included both randomized controlled trials as well as before and after studies such as mirror designs of the same subjects. Studies of STPP delivered in either individual or group format were included.

Search strategy

We searched PsycInfo, 1967-present, Medline 1966-present, and Cochrane Library 2005-present up to July 2007. Many papers had been found in a previous broad search conducted for a Cochrane review of STPP therapies for mental disorders. [19] Our strategy included broad searches with the following terms: psychotherapy, psychodynamic, dynamic or short-term therapy and clinical trial, naturalistic study, or randomized trial and 37 specific terms, such as chest pain, abdominal pain and headache. We searched for further trials by scrutinizing the reference lists of initial studies identified and other relevant review papers. We also contacted selected authors and experts. Two reviewers (AA and SK) independently extracted data. Two reviewers collated and independently assessed abstracts.

Study Description

Studies were reviewed for treatment characteristics, study methodology, sample characteristics, outcome measures, and reported results on primary indices under the categories psychological symptoms, somatic symptoms, social-occupational functioning and healthcare utilization. We specifically noted which studies were manualized, which had adherence ratings and which had blinded ratings of outcome. For randomized controlled trials, we used the Cochrane Collaboration Depression Anxiety and Neurosis (CCDAN) quality rating scale to
numerically rate study quality. This 23 item scale includes a broad range of indicators such as allocation concealment and sample size and has a maximum value of 46.

Meta-analysis

Where appropriate, we combined results of studies using meta-analysis. We used Review Manager version 4.1, a statistical software package for managing and analysing a Cochrane Collaboration systematic review, for our analysis. We divided outcomes into short-term (up to 3 months), medium term (3-9 months) and long-term (over 9 months), and measured effect size (ES) using standardised mean differences. We defined effect sizes as small (ES 0.20-0.49), medium (ES 0.5-0.79) and large (ES ≥ 0.8). [20] We assessed significance using 95% confidence intervals, and heterogeneity by using the Q and I² statistic. A value of greater than 50% for the I² statistic indicates heterogeneity. We assessed for publication bias using the fail-safe N statistic. This is the number of non-significant studies that would be necessary to reduce the effect size (ES) to a negligible value of 0.10. This was calculated using the WinPepi statistical package. [21]

RESULTS:

Study inclusion and characteristics

We found more than 100 citations of interest in initial electronic searches, of which 33 papers were potentially relevant and subjected to strict eligibility assessment. Of these, we excluded 8 which did not meet our inclusion criteria and 2 which were duplicate publications (Figure 1). The 23 eligible studies included 13 randomized controlled trials and 10 pre-post studies. Eighteen focused on specific symptoms or symptom clusters while 5 studied general somatic symptoms or clusters of disorders. Although fifteen studies cited specific STPP models, only six studies described manualized treatments and six noted adherence verification. Nine had blinded ratings of outcome. The CCDAN quality ratings averaged 26.5 (SD 7.3, Range 16-36) suggesting moderate study quality. These studies were performed in 10 different countries over the past 25 years.

Patients

There were a total of 1870 subjects (study range of 10-342), of which 873 (Range 10-87) received STPP and 535 (range 22-257) served as controls. Studies included a mean of 77 (SD 63) patients. Patients averaged 41.3 (SD 10) years of age, and 57.8% (SD 26) were female.

Conditions

The sample was comprised of 13 different medical conditions affecting various major systems including dermatological, neurological, cardiovascular, respiratory, gastrointestinal, musculoskeletal, genitourinary and immunological systems. Six studies involved patients with chronic pain. Some studies included somatic disorders, such as irritable bowel syndrome and chronic pain, which are known to have moderately strong associations with psychological factors. Others included medical conditions which, though manifested by somatic symptoms, are less clearly linked to emotional dysregulation, such as Crohn’s disease, coronary artery disease, emphysema, bronchitis and Sjorgen’s syndrome.

Outcomes

The majority of all measured outcomes showed benefits in either RCTs or pre-post studies. Twenty-one (91.3%) reported significant (N=17) or possible (N=4) symptom benefits related to the main physical condition. Eleven of 12 (91.6%) reported significant (N=9) or possible (N=2) social-occupational function improvements. Sixteen of 21 (76.2%) found significant (N=13) or possible (N=3) psychological symptom benefits. Finally, 7 of 9 (77.8%) reported significant (N=6) or possible (N=1) reductions in healthcare utilization. Outcome
possibly worse than the control was reported in only the bronchitis/emphysema study [22] on some of the symptom measures. In this study, more STPP patients had stopped smoking, perhaps leading to withdrawal, anxiety or depressive symptoms.

Long-term follow up in this set of studies was the norm. Nineteen studies (82.6%) had follow-up of treated cases. The average duration of follow-up was 19.6 (SD 16) months with a range of 1.5 to 60 months.

**Figure 1: Number of papers yielded by search strategy in systematic review**
## Table 1. STPP Study Designs and Outcomes

<table>
<thead>
<tr>
<th>Author</th>
<th>Subjects</th>
<th>Age</th>
<th>Female %</th>
<th>STPP Model</th>
<th>Hours</th>
<th>Follow-up (Mos)</th>
<th>Control</th>
<th>Outcomes *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosser et al 1983 [22]</td>
<td>Chronic Bronchitis and Emphysema</td>
<td>33</td>
<td>66</td>
<td>38</td>
<td>Malan</td>
<td>8</td>
<td>6</td>
<td>Medical treatment +/0/ - 0/- +</td>
</tr>
<tr>
<td>Svedlund &amp; Sjödin 1983 [23]</td>
<td>Irritable Bowel Syndrome, Ulcer Disease</td>
<td>101</td>
<td>70</td>
<td>Malan</td>
<td>&lt;=10</td>
<td>15</td>
<td>Medication +</td>
<td>Anxiolytics + + + +</td>
</tr>
<tr>
<td>Bassett &amp; Pilowsky 1985 [25]</td>
<td>Chronic Pain</td>
<td>22</td>
<td>17</td>
<td>Not defined</td>
<td>12</td>
<td>6, 12</td>
<td>Supportive Cognitive Therapy 0 +/0 0</td>
<td></td>
</tr>
<tr>
<td>Poulsen 1991 [26]</td>
<td>Rheumatoid Arthritis, Sjogren’s Syndrome</td>
<td>46</td>
<td>90</td>
<td>Group analytic</td>
<td>12</td>
<td>9</td>
<td>No treatment + +/0</td>
<td></td>
</tr>
<tr>
<td>Guthrie et al 1993 [27]</td>
<td>Refractory Irritable Bowel Syndrome</td>
<td>102</td>
<td>86</td>
<td>Hobson</td>
<td>7</td>
<td>3</td>
<td>Supportive Therapy + + + +</td>
<td></td>
</tr>
<tr>
<td>Baldoni et al. 1995 [28]</td>
<td>Urethral Syndrome/ Pelvic pain</td>
<td>36</td>
<td>100</td>
<td>Davanloo, Malan</td>
<td>14-16</td>
<td>6, 48</td>
<td>Treatment as Usual + + +</td>
<td></td>
</tr>
<tr>
<td>Hamilton et al, 2000 [32]</td>
<td>Chronic Functional Dyspepsia</td>
<td>77</td>
<td>59.5</td>
<td>Hobson</td>
<td>8</td>
<td>12</td>
<td>Supportive therapy + +/0 0</td>
<td></td>
</tr>
<tr>
<td>Monsen &amp; Monsen 2000 [33]</td>
<td>Chronic Pain</td>
<td>40</td>
<td>35</td>
<td>Affect Focused</td>
<td>33</td>
<td>12</td>
<td>Treatment as usual + + +</td>
<td></td>
</tr>
<tr>
<td>Beresnevaite 2000 [34]</td>
<td>Coronary Heart Disease</td>
<td>40</td>
<td>5</td>
<td>Group</td>
<td>16</td>
<td>6, 12, 24</td>
<td>Education group +/0 + +/0</td>
<td></td>
</tr>
<tr>
<td>Linnet et al 2001 [35]</td>
<td>Atopic Dermatitis</td>
<td>32</td>
<td>23</td>
<td>Malan</td>
<td>15.5</td>
<td>12</td>
<td>Medical Treatment 0 0</td>
<td></td>
</tr>
<tr>
<td>Creed et al. 2003 [36]</td>
<td>Irritable Bowel Syndrome</td>
<td>257</td>
<td>65</td>
<td>Hobson</td>
<td>8</td>
<td>12</td>
<td>Treatment as usual +/0 + +/0 +</td>
<td></td>
</tr>
<tr>
<td>Barnat 1981 [37]</td>
<td>Refractory Headache</td>
<td>79</td>
<td>75.9</td>
<td>Individual STPP</td>
<td>5</td>
<td></td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Sifneos 1984 [38]</td>
<td>Physical Symptoms</td>
<td>14</td>
<td></td>
<td>Sifneos</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neilson et al 1988 [39]</td>
<td>Physical Symptoms</td>
<td>10</td>
<td>70</td>
<td>Sifneos, Malan +</td>
<td>22</td>
<td>24</td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Bassler 1994 [40]</td>
<td>Chronic Pain</td>
<td>50</td>
<td>68</td>
<td>Individual &amp; group</td>
<td>12</td>
<td>1.5</td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Junkert-Tress 2000 [41]</td>
<td>Somatoform Mixed</td>
<td>87</td>
<td>55</td>
<td>Strupp &amp; Binder</td>
<td>60</td>
<td></td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Abbas 2002 [42], 2003 [43]</td>
<td>Somatoform Mixed</td>
<td>33</td>
<td>63.6</td>
<td>Davanloo</td>
<td>18.6</td>
<td>12, 36</td>
<td>+ + + +</td>
<td></td>
</tr>
<tr>
<td>Hawkins 2003 [44]</td>
<td>Chronic Pain</td>
<td>47</td>
<td>64</td>
<td>Davanloo Group</td>
<td>8</td>
<td></td>
<td>+ 0</td>
<td></td>
</tr>
<tr>
<td>Hinson et al 2006 [45]</td>
<td>Movement Disorders</td>
<td>10</td>
<td>77.7</td>
<td>Davanloo</td>
<td>12</td>
<td></td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Tschuschke et al 2007 [46]</td>
<td>Somatoform Disorders</td>
<td>50</td>
<td>62</td>
<td>STPP Group</td>
<td>20</td>
<td>6, 12</td>
<td>+ +</td>
<td></td>
</tr>
<tr>
<td>Ventegodt et al 2007 [47]</td>
<td>Chronic Pain</td>
<td>31</td>
<td></td>
<td>STPP &amp; body work</td>
<td>20</td>
<td>12</td>
<td>+ + +</td>
<td></td>
</tr>
</tbody>
</table>

* S-O= Social-Occupational. +, O and - denote STPP superior to, equal to or inferior to control or pre treatment primary measures. Blank spaces denote no data provided or not applicable.


Meta-analyses

Fourteen studies provided usable data for meta-analyses. We did not include data from a 15th study [24] as this was a study of peptic ulcer from 20 years ago before the introduction of triple therapy for the eradication of Helicobacter pylori. The remainder either did not have outcomes fitting our categories or did not present data in a useable format. The numbers for individual studies vary according to the outcome (e.g. depression, anxiety, somatic and general psychiatric symptoms), and length of follow-up (e.g. short, medium and long-term).

In terms of short-term outcome (0 to 3 months), the fixed effects model showed moderate improvements (ES 0.58-0.78) relative to controls for general psychiatric symptoms, depression, anxiety and somatic symptoms (Figure 2). All these results were significant. The random effects model showed similar results except for somatic symptoms where the difference marginally failed to reach significance (SMD -0.79, 95% confidence interval (CI) -1.69 to +0.18) (Z=1.94, p=0.051).

There were significant differences of at least moderate magnitude in the medium-term for general psychiatric symptoms (SMD -0.56, 95% CI –0.81 to -0.31) (Z=4.35, p <0.0001), depression (SMD -0.84, 95% CI -1.34 to -0.35) (Z=3.31, p<0.001), anxiety (SMD -1.00, 95% CI -1.51 to -0.50) (Z=3.89, p =0.0001) and somatic symptoms (SMD -0.87, 95% CI -1.37 to -0.38) (Z=3.45, p <0.001) using the fixed effects model. The random-effects model produced similar results for all outcomes.

The difference between intervention and control groups was maintained in the long-term (over 9 months) for the fixed effects model (Figure 3). There were also significant differences using the random effects model for general psychiatric symptoms (SMD -1.45, 95% CI -2.87 to -0.03) (Z=2.00, p=0.05). However, there were no significant differences after 9 months between intervention and control groups using the random effects model for depression (SMD -1.48, 95% CI -3.57 to 0.61) (Z=1.32, p=0.19), anxiety (SMD -1.53, 95% CI -3.42 to 0.37) (Z=1.47, p=0.14) or somatic symptoms (SMD -2.21, 95% CI -5.49 to 1.07) (Z=1.32, p=0.19).

Only three studies considered social adjustment or disability and the fixed effects model showed modest, significant improvements relative to controls in the short-term (SMD -0.65, 95% CI -0.91 to -0.40) (Z=3.96, p<0.001), and long-term (SMD -0.69, 95% CI -0.96 to -0.43) (Z=3.60, p<0.001). The random effects model produced identical results.

Ten studies provided data for dropout from STPP treatment versus control conditions. Rates of dropout were significantly higher in the control groups (OR 1.54, 95% CI 1.06-2.25) (Z=2.25, p=0.02), suggesting STPP patients were 54% more likely to stay in treatment.
Figure 2: Meta-analysis of short-term outcomes

<table>
<thead>
<tr>
<th>Study of sub-category</th>
<th>N</th>
<th>GEPP Mean (SD)</th>
<th>N</th>
<th>Control Mean (SD)</th>
<th>SMD (Fixed) 95% CI</th>
<th>Weight %</th>
<th>SMD (Random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 General psychiatric symptom measures: short-term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamilton 2009</td>
<td>37</td>
<td>8.47 (6.88)</td>
<td>37</td>
<td>1.70 (6.53)</td>
<td>4.83 [0.06, 10.61]</td>
<td>25.61</td>
<td>5.83 [0.06, 10.61]</td>
</tr>
<tr>
<td>Morris 2005</td>
<td>20</td>
<td>0.46 (0.49)</td>
<td>20</td>
<td>0.06 (0.46)</td>
<td>2.35 [0.71, 4.97]</td>
<td>9.50</td>
<td>2.35 [0.71, 4.97]</td>
</tr>
<tr>
<td>Junge-Haan 2008</td>
<td>60</td>
<td>5.62 (6.51)</td>
<td>60</td>
<td>1.58 (6.59)</td>
<td>5.17 [-0.70, 10.16]</td>
<td>29.60</td>
<td>5.17 [-0.70, 10.16]</td>
</tr>
<tr>
<td>Allkow 2002</td>
<td>44</td>
<td>9.55 (6.69)</td>
<td>44</td>
<td>3.02 (6.69)</td>
<td>3.33 [-0.75, 7.42]</td>
<td>22.22</td>
<td>3.33 [-0.75, 7.42]</td>
</tr>
<tr>
<td>Oddie 2009</td>
<td>45</td>
<td>5.97 (5.49)</td>
<td>45</td>
<td>0.66 (6.86)</td>
<td>4.03 [0.41, 7.66]</td>
<td>29.55</td>
<td>4.03 [0.41, 7.66]</td>
</tr>
<tr>
<td>Higgins 2006</td>
<td>6</td>
<td>29.00 (29.29)</td>
<td>9</td>
<td>37.80 (6.10)</td>
<td>1.91 [-0.97, 4.79]</td>
<td>40.00</td>
<td>1.91 [-0.97, 4.79]</td>
</tr>
<tr>
<td>Tschalne 2007</td>
<td>10</td>
<td>7.58 (6.43)</td>
<td>10</td>
<td>0.06 (6.43)</td>
<td>0.92 [-0.96, 2.80]</td>
<td>50.00</td>
<td>0.92 [-0.96, 2.80]</td>
</tr>
<tr>
<td>Subtotal (90%) CI</td>
<td>316</td>
<td>115</td>
<td>39.60 [-0.39, -0.62]</td>
<td>Test for overall effect: Z = 7.97 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

02 Depression: short-term

<table>
<thead>
<tr>
<th>Study of sub-category</th>
<th>N</th>
<th>GEPP Mean (SD)</th>
<th>N</th>
<th>Control Mean (SD)</th>
<th>SMD (Fixed) 95% CI</th>
<th>Weight %</th>
<th>SMD (Random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Svedbom 1983</td>
<td>60</td>
<td>2.34 (6.22)</td>
<td>60</td>
<td>3.55 (6.49)</td>
<td>2.11 [-2.26, -2.94]</td>
<td>52.34</td>
<td>2.11 [-2.26, -2.94]</td>
</tr>
<tr>
<td>Oddie 2009</td>
<td>44</td>
<td>13.18 (10.52)</td>
<td>44</td>
<td>12.85 (10.74)</td>
<td>5.42 [-1.52, 2.57]</td>
<td>22.22</td>
<td>5.42 [-1.52, 2.57]</td>
</tr>
<tr>
<td>Jettechen 1996</td>
<td>62</td>
<td>7.80 (10.70)</td>
<td>62</td>
<td>2.00 (2.00)</td>
<td>6.46 [-0.46, 13.36]</td>
<td>29.55</td>
<td>6.46 [-0.46, 13.36]</td>
</tr>
<tr>
<td>Morris 2005</td>
<td>20</td>
<td>0.46 (0.46)</td>
<td>20</td>
<td>0.06 (0.46)</td>
<td>2.35 [-0.71, 4.97]</td>
<td>9.50</td>
<td>2.35 [-0.71, 4.97]</td>
</tr>
<tr>
<td>Allkow 2002</td>
<td>44</td>
<td>9.55 (6.69)</td>
<td>44</td>
<td>3.02 (6.69)</td>
<td>3.33 [-0.75, 7.42]</td>
<td>22.22</td>
<td>3.33 [-0.75, 7.42]</td>
</tr>
<tr>
<td>Higgins 2006</td>
<td>6</td>
<td>29.00 (29.29)</td>
<td>9</td>
<td>37.80 (6.10)</td>
<td>1.91 [-0.97, 4.79]</td>
<td>40.00</td>
<td>1.91 [-0.97, 4.79]</td>
</tr>
<tr>
<td>Subtotal (90%) CI</td>
<td>316</td>
<td>115</td>
<td>19.41 [-1.15, -0.74]</td>
<td>Test for overall effect: Z = 8.60 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

03 Anxiety: short-term

<table>
<thead>
<tr>
<th>Study of sub-category</th>
<th>N</th>
<th>GEPP Mean (SD)</th>
<th>N</th>
<th>Control Mean (SD)</th>
<th>SMD (Fixed) 95% CI</th>
<th>Weight %</th>
<th>SMD (Random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Svedbom 1983</td>
<td>60</td>
<td>4.03 (3.39)</td>
<td>60</td>
<td>5.84 (3.39)</td>
<td>1.94 [-1.88, -3.44]</td>
<td>52.34</td>
<td>1.94 [-1.88, -3.44]</td>
</tr>
<tr>
<td>Oddie 2009</td>
<td>44</td>
<td>13.18 (10.52)</td>
<td>44</td>
<td>12.85 (10.74)</td>
<td>5.42 [-1.52, 2.57]</td>
<td>22.22</td>
<td>5.42 [-1.52, 2.57]</td>
</tr>
<tr>
<td>Jettechen 1996</td>
<td>62</td>
<td>7.80 (10.70)</td>
<td>62</td>
<td>2.00 (2.00)</td>
<td>6.46 [-0.46, 13.36]</td>
<td>29.55</td>
<td>6.46 [-0.46, 13.36]</td>
</tr>
<tr>
<td>Morris 2005</td>
<td>20</td>
<td>0.46 (0.46)</td>
<td>20</td>
<td>0.06 (0.46)</td>
<td>2.35 [-0.71, 4.97]</td>
<td>9.50</td>
<td>2.35 [-0.71, 4.97]</td>
</tr>
<tr>
<td>Allkow 2002</td>
<td>44</td>
<td>9.55 (6.69)</td>
<td>44</td>
<td>3.02 (6.69)</td>
<td>3.33 [-0.75, 7.42]</td>
<td>22.22</td>
<td>3.33 [-0.75, 7.42]</td>
</tr>
<tr>
<td>Higgins 2006</td>
<td>6</td>
<td>29.00 (29.29)</td>
<td>9</td>
<td>37.80 (6.10)</td>
<td>1.91 [-0.97, 4.79]</td>
<td>40.00</td>
<td>1.91 [-0.97, 4.79]</td>
</tr>
<tr>
<td>Subtotal (90%) CI</td>
<td>316</td>
<td>115</td>
<td>18.86 [-1.86, -0.32]</td>
<td>Test for overall effect: Z = 8.64 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

04 Somato-somatic symptoms: short-term

<table>
<thead>
<tr>
<th>Study of sub-category</th>
<th>N</th>
<th>GEPP Mean (SD)</th>
<th>N</th>
<th>Control Mean (SD)</th>
<th>SMD (Fixed) 95% CI</th>
<th>Weight %</th>
<th>SMD (Random) 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Svedbom 1983</td>
<td>60</td>
<td>9.72 (6.74)</td>
<td>60</td>
<td>12.09 (6.52)</td>
<td>2.31 [-2.76, -0.86]</td>
<td>52.34</td>
<td>2.31 [-2.76, -0.86]</td>
</tr>
<tr>
<td>Oddie 2009</td>
<td>44</td>
<td>7.20 (4.29)</td>
<td>44</td>
<td>7.00 (4.29)</td>
<td>0.47 [0.14, 0.81]</td>
<td>22.22</td>
<td>0.47 [0.14, 0.81]</td>
</tr>
<tr>
<td>Morris 2005</td>
<td>20</td>
<td>3.35 (1.50)</td>
<td>20</td>
<td>3.00 (1.50)</td>
<td>2.30 [-0.10, 5.71]</td>
<td>22.22</td>
<td>2.30 [-0.10, 5.71]</td>
</tr>
<tr>
<td>Allkow 2002</td>
<td>44</td>
<td>9.55 (6.69)</td>
<td>44</td>
<td>3.02 (6.69)</td>
<td>3.33 [-0.75, 7.42]</td>
<td>22.22</td>
<td>3.33 [-0.75, 7.42]</td>
</tr>
<tr>
<td>Higgins 2006</td>
<td>6</td>
<td>29.00 (29.29)</td>
<td>9</td>
<td>37.80 (6.10)</td>
<td>1.91 [-0.97, 4.79]</td>
<td>40.00</td>
<td>1.91 [-0.97, 4.79]</td>
</tr>
<tr>
<td>Subtotal (90%) CI</td>
<td>316</td>
<td>115</td>
<td>27.80 [-2.70, 0.06]</td>
<td>Test for overall effect: Z = 10.75 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

-40 -30 -20 -10 0 5 10
Heterogeneity

Although the number of studies that reported any given outcome was small, we calculated formal tests of heterogeneity. These were significant in the majority of all our meta-analyses. They were only non-significant for medium term outcomes and social adjustment. Similarly, the I² statistic was consistently greater than 50% for both short and long-term outcomes, although less so for medium term outcomes. The results of our meta-analyses should therefore be interpreted with caution.

Sensitivity analyses

We conducted sensitivity analyses of the effect of only including RCTs. [23,25,27,28,29,32,33,35,36] The fixed-effects model results remained significant for all outcomes. Using the random effects model, medium term outcomes were unaltered, but, results were no longer significant for any of the short or long-term outcomes.

Restricting analyses to studies with high CCDAN scores, defined as a score of greater than the mid-point of the scale (>18), gave identical results to considering only RCTs.

We also conducted a sensitivity analysis to examine the effects of emotion-focused versus insight-based, or interpersonally focused approaches, by meta-analyzing studies that emphasized emotional experiencing in their technical description. [28,33,42,44,45] The effects using both the fixed and random effects models were significant with medium to large effect sizes on all measures in the short-term (Fixed Effect Sizes 0.60-1.10) and medium-term (Fixed Effect Sizes 0.81-1.31). There were insufficient studies to undertake meta-analyses of the long-term outcomes.

Finally, we conducted sensitivity analyses of the effect of only including studies with evaluation of therapy adherence. [29,32,33,36,41,42] The fixed-effects model results remained significant for all outcomes. Using the random effects model, results were significant for general psychiatric symptoms (SMD -0.54, 95% CI -0.96 to -0.12) (Z=2.53, p=0.01) and depression.
(SMD -0.60, 95% CI -1.09 to -0.11) \((Z=2.42, p=0.02)\) but not anxiety or somatic symptoms in the short-term. There were insufficient studies to undertake meta-analyses of the medium- and long-term outcomes.

**Publication Bias**

The fail-safe \(N\) for short-term effectiveness ranged between 41 and 56, depending on the outcome, suggesting that these findings were reasonably robust against publication bias. For medium term outcomes, the fail-safe \(N\) was between 16 and 19 indicating that these results were more subject to publication bias. In the long-term, our findings for depression and anxiety (fail-safe \(Ns\) of 42 and 44 respectively) were more robust against publication bias than those for general psychiatric and somatic symptoms (fail-safe \(Ns\) of 14 and 12 respectively). When we calculated the fail-safe \(N\) for our sensitivity analyses, numbers were reduced for the short-term outcomes, but there was little effect on those medium to long term outcomes where meta-analyses were possible. For instance, the fail-safe \(N\) for short-term effectiveness from RCTs ranged between 29 and 38.

**Other Studies and Findings**

Nine studies did not meet criteria for inclusion in the meta-analysis, yet provided preliminary evidence supporting STPP for a range of conditions (Table 1).

Despite known bacteriological causes of ulcer, Sjodin [24], found that STPP brought sustained gains compared to medical treatment as usual in ulcer patients.

Bassler et al [39] studied a 12-week inpatient treatment program for chronic “psychogenic” pain that included individual and group STPP. Sixty percent of patients reported amelioration of pain symptoms. Those who intellectualized and rationalized more had less response to treatment, highlighting the purported role of emotional experiencing in bringing symptom amelioration.

Case series for physical symptoms yielded improvement rates of 76% to 90%. [37-39] Ventegodt [47] using a combination of STPP and “body work”, found significant symptom improvements in a mixed group of physically ill patients although a large portion of the sample was lost to follow-up.

Two studies [26, 34] examined the impact of STPP on alexithymia. Beresnevaite found that reductions in alexithymia were associated with fewer cardiac events in 2 year follow-up of patients with coronary artery disease. While the treatment and control groups did not significantly differ in degree of alexithymia at post treatment, the STPP group had no hospitalizations plus reduced reports of angina while controls had 4 hospitalizations for angina. Poulsen et al found that rheumatoid arthritis and Sjrogens’ Syndrome patients treated with group STPP had lower alexithymia ratings compared to controls at post-treatment, but they did not have pre-treatment measurements.

Reduced hospitalization rates compared to controls was reported in studies of STPP for coronary artery disease [34] \((X^2, p<.01)\), Crohn’s disease [30] \((p=.03)\) and chronic respiratory disease [22] \((X^2, p<.001)\). Two studies reported trends toward reduced surgical procedures in ulcer disease [24] \((p=.07)\) and in Crohn’s disease [29] where 15% of STPP patients vs 26% of controls required surgery \((p=.27)\).

**DISCUSSION**

Within the limitations of study quality and the effects of heterogeneity on statistical interpretability, the evidence from this review suggests that short-term psychodynamic psychotherapy methods show promise as adjunctive or solo treatments for a range of somatic
problems. In addition to reducing physical and psychological symptoms, these brief treatments appeared to improve treatment compliance, improve social-occupational function and reduce healthcare utilization. These improvements were noted in the majority of studies as measured by blinded clinicians, unblinded clinicians, and patient self-ratings.

These results compare favorably to a similarly conducted review of CBT for somatic disorders. [10]. This study included 29 RCT and 2 non RCT studies of diverse conditions with a variety of CBT methods and group and individual formats. In this review, only 9 stated they used manuals and 7 had adherence ratings. They found definite or possible symptom benefits in 82%, functional benefits in 73%, and psychological benefits in 46% of included studies.

Likewise, 91.3% of STPP studies showed at least some benefit (on one or more parameter) for these patient populations compared to 69% of antidepressant studies in a systematic review of 94 randomized trials. [9] Moreover, the antidepressant studies were only short-term with a median duration of 9 weeks compared to the long-term follow-up in the majority of the STPP studies. Recent literature syntheses confirm that CBT and antidepressants are among the most evidence-based treatments for somatic symptom disorders. [13, 14] Our findings suggest STPP may be another valuable therapeutic option.

Emotional factors, including reduced alexithymia, building awareness of unconscious processes and emotional experiencing are possible or probable treatment factors rendering these therapies effective. This notion is bolstered by our subanalysis showing strong effects when studying the more emotion-focused STPP models. This finding concurs with a recent meta-analysis of 10 STPP studies of diverse conditions showing that outcome correlated with emotional focus. [49] Comparative study of the more emotion-focused versus insight-based models are warranted to test the hypothesis that emotional experiencing has a central healing effect in these somatic disorders as this research suggests.

The somewhat positive results of this review should be interpreted within the following limitations. First, the included studies were of variable methodological quality, conducted with a broad range of scientific rigor. Second, there is a high probability of selection bias in some of the studies although in the 13 RCTs the use of randomization should have mitigated between-group differences as a confounder. Third, there is likely reporting bias, where striking positive (stopping smoking) or negative events (vagotomy surgery) would be more likely reported in only some studies. Fourth, most of the treatments were neither manualized nor adherence rated to ensure treatment standardization. Fifth, only 4 and 5 of the studies in the meta-analysis had medium and long-term follow-ups respectively. Finally, the heterogeneity in most meta-analyses, the loss of significance in some cases using random effects modeling, and the inclusion of only 14 studies suggest that the meta-analysis results need to be interpreted with caution.

This heterogeneity may have arisen from both clinical or methodological diversity, or both, among the studies [47]. In this study clinical variation could be explained by the diversity of the psychotherapeutic interventions that were included in the review (e.g. group versus individual therapy formats), as well as of subjects in terms of diagnoses (e.g. Crohn’s disease versus movement disorders) and socio-demographics (e.g. age and gender). Methodological diversity could be explained by differences between studies in terms of design (e.g. randomised versus non-randomised designs) or in the way the outcomes were defined and measured. We attempted to minimise heterogeneity in several ways. Firstly, we did not report combined effect sizes for short, medium, and long-term outcomes, but reported the results for depression, anxiety and somatic symptoms separately. Secondly, we undertook sensitivity analyses restricted to
randomised control trials, higher quality studies and adherence rated therapies. Thirdly, we also
reported random-effects meta-analyses, which incorporate heterogeneity in their calculation.

One strength of the reviewed studies is the diversity of study centers and the inclusion of
both RCTs as well as case series and naturalistic studies. The latter studies offer evidence that
some patients with this range of conditions can benefit in real world settings with improvements
in psychological functioning, physical symptoms and healthcare utilization. The finding that a
broad range of conditions may benefit from this treatment suggests STPP may provide a general
health benefit.

Greater retention rates with STPP and reduced healthcare utilization are important
findings. Conditions such as movement disorders, chronic pain, headache, and other conditions
are often treated with medications and physical procedures as first line agents. Given the
availability of brief psychotherapeutic interventions, STPP therapy might be one option
clinicians could consider before embarking on more invasive or long-term alternatives.

Within the limitations of methodological and other problems within this group of studies,
STPP may provide benefits across a range of physical and somatic symptom disorders. Future
research should include more rigorous research methods and study specific conditions while
using treatment manuals with adherence ratings. Combinations of RCT and naturalistic studies
measuring healthcare utilization and mortality rates are also warranted. STPP can be considered
as a solo treatment for some somatic conditions and an adjunct for other physical conditions that
may improve treatment retention and outcome.

References

1. Kroenke K: Patients presenting with somatic complaints: epidemiology, psychiatric

2. Aaron LA, Buchwald D: A review of the evidence for overlap among unexplained clinical

3. Henningsen P, Zimmermann T, Sattel H: Medically unexplained physical symptoms, anxiety,

4. Kroenke K, Rosmalen JG: Symptoms, syndromes, and the value of psychiatric diagnostics in

Primary Care Companion 2003;5 [suppl 7]:11-18.

6. Sha MC, Callahan CM, Counsell SR, Westmoreland GR, Stump TE, Kroenke K: Physical
symptoms as a predictor of health care use and mortality among older adults. Am J Med

symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29(2):147-
155.


